Association between PD‐1 inhibitor‐related adverse events and frailty assessed by frailty index in lung cancer patients

BACKGROUND: The programmed cell death protein 1 (PD‐1) inhibitor, as one of the immune checkpoint inhibitors (ICIs), is the standard treatment for advanced lung cancer. However, immune‐related adverse events (irAEs) remain poorly understood toxicities. It is unclear whether frailty plays a role in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jun, Zhang, Xiaolin, Zhou, Shuang, Zhou, Ying, Liu, Xinmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166957/
https://www.ncbi.nlm.nih.gov/pubmed/36727563
http://dx.doi.org/10.1002/cam4.5669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166957/
https://www.ncbi.nlm.nih.gov/pubmed/36727563
http://dx.doi.org/10.1002/cam4.5669

Ejemplares similares